Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 5Other hematologic neoplasm 5Thoracic 4Lymphoid 3Gastrointestinal 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Head & Neck 2Genitourinary 2Dermatologic 2Breast 2Gynecologic 1CNS 1

Conditions

Skin Neoplasms 2Melanoma 2

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cisplatin 15Fluorouracil 14Cyclophosphamide 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Tablets × Dermatologic × Clear all
NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

NCT00083252 2007-06-08

Study of Talabostat and Cisplatin in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡